Asthma Treatment — Cost, Top Hospitals & Success Rates | MyMedicPlus

Asthma is a chronic inflammatory disease of the airways characterised by variable airflow obstruction and bronchial hyperresponsiveness. The underlying pathology involves infiltration of the airway wall by eosinophils, mast cells, and T lymphocytes, with structural changes (airway remodelling) occurring over time in inadequately treated disease. Symptoms — recurrent wheezing, breathlessness, chest tightness, and cough, typically worse at night and early morning — result from bronchoconstriction, mucosal oedema, and increased mucus secretion in response to triggers.

Treatment follows the GINA stepwise framework, aiming to achieve symptom control (no daytime symptoms, no night awakenings, no activity limitation, SABA use ≤ twice per week) and reduce future risk of exacerbations, fixed airflow limitation, and treatment side effects. Inhaled corticosteroids (ICS) are the cornerstone of preventer therapy at all steps above intermittent mild asthma, reducing airway eosinophilic inflammation and exacerbation risk by 50–70% compared to reliever-only treatment.

The patient journey begins with clinical assessment and spirometry confirming variable airflow obstruction (FEV1/FVC ratio, bronchodilator reversibility ≥ 12% and 200 mL), fractional exhaled nitric oxide (FeNO) measurement as a biomarker of airway eosinophilic inflammation, and identification of the asthma phenotype and treatable traits to guide personalised therapy selection.

Asthma treatment addresses all phenotypes including allergic asthma (most common — IgE-mediated, triggered by specific allergens, onset in childhood or early adulthood, associated with atopic comorbidities), non-allergic asthma (adult-onset, no atopic sensitisation, often triggered by respiratory infections and irritants), late-onset eosinophilic asthma (adult-onset, high blood eosinophils, often severe and steroid-dependent), aspirin-exacerbated respiratory disease (AERD — asthma, chronic rhinosinusitis, and nasal polyps triggered by NSAIDs), and exercise-induced bronchoconstriction.

Severe uncontrolled asthma — requiring high-dose ICS-LABA with additional controllers and/or frequent oral corticosteroid courses to prevent loss of control — is the key indication for add-on biologic therapy. Occupational asthma caused by sensitising workplace agents (isocyanates, flour dust, latex) requires removal from exposure as the primary intervention, with pharmacological management for residual disease.

All confirmed asthma patients are candidates for stepwise pharmacological management. Candidates for biologic therapy must have confirmed severe uncontrolled asthma despite optimised ICS-LABA with adherence verified, correctly treated comorbidities (allergic rhinitis, GERD, obesity, sleep apnoea), and a measurable treatable trait — elevated IgE for omalizumab; blood eosinophilia ≥ 300 cells/µL for mepolizumab, benralizumab; high FeNO or eosinophilia for dupilumab; any severe asthma phenotype for tezepelumab.

Contraindications include beta-blocker use (contraindicated in asthma), aspirin and NSAIDs in AERD patients (unless undergoing supervised aspirin desensitisation), and active smoking as a major modifier of ICS response. Patients with severe asthma and fixed airflow obstruction (post-bronchodilator FEV1 < 60% predicted) should be evaluated for COPD comorbidity or asthma-COPD overlap syndrome, which requires a modified treatment approach.

ICS formulations include beclometasone dipropionate (BDP), budesonide, fluticasone propionate (FP), fluticasone furoate (FF), ciclesonide, and mometasone. ICS-LABA combinations (budesonide-formoterol, fluticasone-salmeterol, fluticasone furoate-vilanterol) provide synergistic anti-inflammatory and bronchodilatory effects. The SMART (Single Maintenance And Reliever Therapy) approach using budesonide-formoterol as both daily controller and as-needed reliever reduces severe exacerbation risk by 50% compared to fixed-dose ICS-LABA with SABA reliever.

Add-on therapies for uncontrolled asthma include long-acting muscarinic antagonists (tiotropium), leukotriene receptor antagonists (montelukast), sustained-release theophylline (now rarely used due to narrow therapeutic window), and azithromycin (for non-eosinophilic frequent-exacerbator phenotype). Biologic agents — omalizumab (anti-IgE), mepolizumab and benralizumab (anti-IL-5/IL-5Rα), dupilumab (anti-IL-4Rα), and tezepelumab (anti-TSLP) — are transforming management of severe asthma, achieving exacerbation reductions of 50–70% and enabling oral corticosteroid tapering in corticosteroid-dependent patients.

Selecting the most appropriate Asthma Treatment approach requires a structured assessment of patient-specific factors. The treating specialist evaluates disease severity, prior treatment history, comorbidities, and patient preferences before recommending a specific protocol. Combination approaches are often more effective than monotherapy — integrating pharmacological, procedural, or rehabilitative elements to address multiple disease mechanisms simultaneously. Dose or intensity is titrated incrementally based on clinical response, tolerability, and objective outcome measures. In patients with refractory disease or inadequate response to first-line protocols, escalation to higher-intensity or specialist-delivered treatment options is indicated. Multidisciplinary team (MDT) review ensures that surgical, medical, and allied health perspectives are integrated into the final management plan, particularly for complex or high-risk cases where multiple treatment pathways are viable and the risk-benefit balance requires careful deliberation.

Optimised ICS-based therapy achieves good symptom control (Asthma Control Test score ≥ 20) in 70–80% of patients and reduces severe exacerbation rates by 50–70%. SMART therapy reduces both total ICS dose and exacerbation frequency compared to conventional maintenance-plus-SABA regimens. Biologic therapies achieve ≥ 50% exacerbation reduction in 60–80% of appropriately selected patients with measurable treatable traits, with complete elimination of oral corticosteroid dependence in many.

Long-term benefits of effective asthma management include prevention of airway remodelling (structural changes that can cause irreversible fixed airflow obstruction), preserved lung function trajectory, normal or near-normal activity including sport, reduced emergency visits and hospitalisations, and the ability to live, work, and travel without significant asthma limitation. Patient education about trigger avoidance, inhaler technique, and an personalised Asthma Action Plan reduces the risk of life-threatening attacks.

ICS at recommended doses are safe for long-term use. Side effects include oropharyngeal candidiasis and dysphonia (minimised by rinsing the mouth after use and using a spacer device). High-dose ICS (BDP equivalent > 1000 µg/day) may cause measurable but clinically small reductions in bone density and very mild adrenal suppression. Oral corticosteroids — required for severe exacerbations and some severe asthma management — cause weight gain, diabetes, hypertension, osteoporosis, cataracts, and adrenal suppression with prolonged use.

Untreated or inadequately treated asthma is the primary risk — severe asthma attacks can cause respiratory failure requiring mechanical ventilation, and asthma causes approximately 1,000 deaths annually in the UK and 3,500 in the US, the majority of which are preventable with guideline-concordant care. Delayed or absent ICS prescribing and poor inhaler technique are the leading modifiable causes of preventable asthma deaths.

Asthma review frequency depends on severity: every 3–6 months when stable, within 1–4 weeks after significant exacerbation or treatment change, and annually as a minimum for all patients. Each review assesses symptom control using the Asthma Control Test (ACT), inhaler technique, treatment adherence, exacerbation history, and current peak flow or spirometry. Step-down of therapy can be attempted after 3 months of consistently good control.

Patients on biologic therapy receive subcutaneous injections every 4–8 weeks (depending on the agent) and are reviewed at 3–4-month intervals. Blood eosinophil counts, FeNO, and exacerbation rates are monitored to assess biologic response. Patients with severe asthma benefit from multidisciplinary review including a specialist respiratory physiotherapist, psychologist, and social support to address breathing pattern disorders, anxiety, and occupational factors.

ICS inhalers cost USD 100–350 per month in the United States without insurance; in India and Thailand branded ICS inhalers cost USD 8–30 per month. Biologic agents cost USD 15,000–35,000 per year in the US; in India some biologics are available as biosimilars or branded generics at 40–70% lower cost. Spirometry, FeNO testing, and allergy skin prick testing for asthma workup cost USD 200–800 in the US and USD 30–100 at private clinics in India or Thailand.

Medical tourism for comprehensive asthma evaluation, biologic therapy initiation, and patient education at specialist respiratory centres in India offers savings of 50–70% compared to US costs. Patients should ensure continuity of biologic prescribing on return home and carry a detailed treatment plan from the treating specialist.

Bronchial thermoplasty is a bronchoscopic procedure delivering radiofrequency energy to reduce airway smooth muscle mass, approved for adults with severe refractory asthma who remain uncontrolled despite maximum pharmacotherapy. It reduces severe exacerbation rates and emergency visits at 5-year follow-up, though patient selection requires careful multidisciplinary evaluation.

Breathing retraining — including the Buteyko breathing technique and physiotherapy-directed breathing pattern retraining — has randomised trial evidence for symptom improvement and reduced reliever use as an adjunct to medical therapy. Allergen immunotherapy (as described in the Asthma-Allergy section) is disease-modifying for allergic asthma. Complementary approaches such as yoga-based breathing, acupuncture, and omega-3 fatty acid supplementation have limited but some supporting evidence as adjuncts; they should not replace evidence-based pharmacotherapy.